107 related articles for article (PubMed ID: 11103240)
1. [Evaluation of adverse effects including neurotoxicity of combination chemotherapy with paclitaxel and carboplatin].
Tate S; Iwasaki H; Matsui H; Hirai Y; Sekiya S
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2087-95. PubMed ID: 11103240
[TBL] [Abstract][Full Text] [Related]
2. [Neurotoxicity of weekly TP (weekly paclitaxel + consecutive low-dose CDDP) therapy].
Tate S; Hirai Y; Iwasaki H; Matsui H; Sekiya S; Hasumi K
Gan To Kagaku Ryoho; 2004 Jan; 31(1):67-73. PubMed ID: 14750324
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
[TBL] [Abstract][Full Text] [Related]
5. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
6. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
9. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
10. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
[No Abstract] [Full Text] [Related]
11. Intraperitoneal chemotherapy for ovarian cancer.
Anastasia P
Oncol Nurs Forum; 2012 Jul; 39(4):346-9. PubMed ID: 22750892
[No Abstract] [Full Text] [Related]
12. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Kumagai M; Fujii T; Komatsu M; Kusuda T; Takehara K; Shinkou S; Naitou H
Gan To Kagaku Ryoho; 2004 Apr; 31(4):555-9. PubMed ID: 15114699
[TBL] [Abstract][Full Text] [Related]
13. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
14. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
15. [Safety evaluation of adjuvant chemotherapy by weekly paclitaxel combined with weekly carboplatin in patients with postoperative non-small cell lung cancer].
Hirose T; Nagao T; Kajikawa A; Sumi T; Sugimoto T; Hirose Y; Yoshida M; Kenzaki K
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1397-400. PubMed ID: 17876136
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of arthralgia and myalgia from paclitaxel and carboplatin combination chemotherapy with Shakuyaku-kanzo-to].
Fujiwara H; Urabe T; Ueda K; Mizunoe T; Date K; Nakano M; Honda N; Sakashita T; Fujito N
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1061-4. PubMed ID: 10925696
[No Abstract] [Full Text] [Related]
18. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced exacerbation of glomus tumour pain.
Daghir A; Anand P; Gabra H; Elliot D
J Hand Surg Br; 2006 Dec; 31(6):692. PubMed ID: 16766103
[No Abstract] [Full Text] [Related]
20. Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin.
Yamamoto K; Hoshiai H; Noda K
Gynecol Oncol; 2001 May; 81(2):333-4. PubMed ID: 11330975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
